237 related articles for article (PubMed ID: 29413049)
1. High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
Park KS; Moon YW; Raffeld M; Lee DH; Wang Y; Giaccone G
Lung Cancer; 2018 Feb; 116():38-45. PubMed ID: 29413049
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.
Xu CH; Sheng ZH; Hu HD; Hao KK; Wang QB; Yu LK
Tumour Biol; 2014 Sep; 35(9):8673-8. PubMed ID: 24870591
[TBL] [Abstract][Full Text] [Related]
3. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis.
Wei Y; Jiang J; Wang C; Zou H; Shen X; Jia W; Jin S; Zhang L; Hu J; Yang L; Pang L
Biomark Med; 2020 Mar; 14(4):317-329. PubMed ID: 32134335
[No Abstract] [Full Text] [Related]
6. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Shen Y; Tang D; Yao R; Wang M; Wang Y; Yao Y; Li X; Zhang H
Med Oncol; 2013 Dec; 30(4):750. PubMed ID: 24198203
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic value of Cripto-1 in early non-small cell lung cancer.
Zhong J; Li L; Zhang Q; Zou J; Liu W; Xu CH
Clin Respir J; 2023 Dec; 17(12):1203-1208. PubMed ID: 37528674
[TBL] [Abstract][Full Text] [Related]
8. Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.
Liu Q; Cui X; Yu X; Bian BS; Qian F; Hu XG; Ji CD; Yang L; Ren Y; Cui W; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Mol Cancer; 2017 Apr; 16(1):81. PubMed ID: 28431580
[TBL] [Abstract][Full Text] [Related]
9. Cripto-1 expression in patients with clear cell renal cell carcinoma is associated with poor disease outcome.
Xue YJ; Chen SN; Chen WG; Wu GQ; Liao YF; Xu JB; Tang H; Yang SH; He SY; Luo YF; Wu ZH; Huang HW
J Exp Clin Cancer Res; 2019 Aug; 38(1):378. PubMed ID: 31455359
[TBL] [Abstract][Full Text] [Related]
10. MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance.
Luo L; Zhang T; Liu H; Lv T; Yuan D; Yao Y; Lv Y; Song Y
Med Oncol; 2012 Sep; 29(3):1681-6. PubMed ID: 21993632
[TBL] [Abstract][Full Text] [Related]
11. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma.
Tejero R; Navarro A; Campayo M; Viñolas N; Marrades RM; Cordeiro A; Ruíz-Martínez M; Santasusagna S; Molins L; Ramirez J; Monzó M
PLoS One; 2014; 9(7):e101899. PubMed ID: 25003366
[TBL] [Abstract][Full Text] [Related]
12. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA; Ebert EBF; Clement MS; Winther-Larsen A; Meldgaard P; Sorensen B
Lung Cancer; 2019 Sep; 135():92-96. PubMed ID: 31447008
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
14. The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.
Goto A; Tanaka M; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Kuriyama S; Konno H; Imai K; Saito H; Minamiya Y; Maeda D
PLoS One; 2017; 12(7):e0181270. PubMed ID: 28704499
[TBL] [Abstract][Full Text] [Related]
15. MiR-15a-16 represses Cripto and inhibits NSCLC cell progression.
Chen F; Hou SK; Fan HJ; Liu YF
Mol Cell Biochem; 2014 Jun; 391(1-2):11-9. PubMed ID: 24500260
[TBL] [Abstract][Full Text] [Related]
16. Expression of Cripto-1 predicts poor prognosis in stage I non-small cell lung cancer.
Xu C; Yuan Q; Hu H; Wang W; Zhang Q; Li L; Wang J; Yang R
J Cell Mol Med; 2020 Sep; 24(17):9705-9711. PubMed ID: 32697011
[TBL] [Abstract][Full Text] [Related]
17. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
18. Cripto-1 expression and its prognostic value in human bladder cancer patients.
Wei B; Jin W; Ruan J; Xu Z; Zhou Y; Liang J; Cheng H; Jin K; Huang X; Lu P; Hu Q
Tumour Biol; 2015 Feb; 36(2):1105-13. PubMed ID: 25326807
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
20. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
